Kuros Biosurgery granted U.S. patent for synthetic hydrogel technology

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced today that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No.

See the original post:
Kuros Biosurgery granted U.S. patent for synthetic hydrogel technology

Share

Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Our research into gynaecological oncology focuses around understanding mechanisms of how genes are regulated or how they become dysregulated in a disease; and also the effects that has on the surface of the endometrium and also the function of the ovaries…

View the original here:
Epigenetics and women’s health research: an interview with Professor Steve Conlan, Swansea University

Share

Study reveals how household net worth affects breast cancer care

Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care. The findings suggest that physicians, health insurers, and policy makers need to pay more attention to this economic variable to ensure that breast cancer patients receive this potentially life-saving treatment.

Read More:
Study reveals how household net worth affects breast cancer care

Share

Predicting the Future of Cancer Surgery

Add a Comment By Jim Stallard, MA, Writer/Editor   |  Tuesday, February 24, 2015 Peter Scardino , Chair of MSK’s Department of Surgery, gives his views on what lies ahead for the surgical treatment of cancer. read more

See more here:
Predicting the Future of Cancer Surgery

Share

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

View post:
Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Share

The Na Pali Coast in Kaua’i, Hawaii

I stole away for an afternoon on Kaua’i, Hawaii, to run/hike the 11-mile Kalalau Trail along the Na Pali Coast this last week.  Although the trail was quite technical (often too technical or overgrown to run), it was a worthy adventure! The Kalalau Trail is at the northern point of Kaua’i, about an hours drive from Lihue Airport, literally at the end of the highway. It’s a popular tourist destination, so best to hit it as soon as the sun comes up

See the original article here:
The Na Pali Coast in Kaua’i, Hawaii

Share